Profiles of urine samples taken from ecstasy users at rave parties: Analysis by immunoassays, HPLC, and GC-MS

Journal of Analytical Toxicology

Volumn 25, Issue 4, 2001, Pages 258-269

  Zhao, Huiru ^a   Brenneisen, Rudolf ^b   Scholer, Andre ^c   McNally, A J ^a   Elsohly, Mahmoud A ^d   Murphy, Timothy P ^d   Salamone, Salvatore J ^a  

^a Roche Diagnostics Corporation   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d ElSohly Laboratories Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; METHAMPHETAMINE;

ARTICLE; CROSS REACTION; DRUG ABUSE; DRUG STRUCTURE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; URINE;

EID: 0035013766     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/25.4.258     Document Type: Article

References (47)

1. H.H. Maurer. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 18: 465-470 (1996).
2. N. Sondermann and K.-A. Kovar. Screening experiments of ecstasy street samples using near infrared spectroscopy. Forensic Sci. Int. 106: 147-156 (1999).
3. E. Gouzoulis, A. Steiger, H.K. Ensslin, K.A. Kovar, and L. Hermle. Sleep EEG effects of 3,4-methylenedioxyethylamphetamine (MDE, "Eve") in healthy volunteers. Biol. Psychiatry 32: 1108-1117 (1992).
4. D.E. Nichols, A.J. Hoffman, R.A. Oberlender, P. Jacob, and A.T. Shulgin. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamines: representatives of a novel therapeutic class. J. Med. Chem. 29: 2009-2015 (1986).
5. D.E. Nichols. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs 18: 305-313 (1986).
6. G. Battaglia, S.Y. Yeh, and E.B. De Souza. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem Behav. 29: 269-274 (1988).
7. G. Ricaurte, L.E. De Lanney, I. Irwin, and J.W. Langston. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446: 165-168 (1988).
8. R. Insel, G. Battaglia, J.N. Johannessen, S. Marra, and E.B. De Souza, 3,4-Methylenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin terminals in Rhesus monkeys. J. Pharmacol. Exp. Ther. 249: 713-720 (1989).
9. J.W. Gibb, D. Stone, M. Johnson, and G.R. Hanson. Neurochemical effects of MDMA. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA, S.J. Peroutka, Ed. Kluwer Academic Publishers, Boston, MA, 1990, pp 133-150.
10. C.J. Schmidt and V.L. Taylor. Neurochemical effects of methylenedioxymethamphetamine in the rat: acute versus long-term changes. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA, S.J. Peroutka, Ed. Kluwer Academic Publishers, Boston, MA, 1990, pp 151-169.
11. G. Battaglia, R. Zaczek, and E.B. De Souza. MDMA effects in brain: profile and evidence of neurotoxicity from neurochemical and autoradiographic studies. In Ecstasy: The Clinical Pharmacological and Neurotoxicological Effects of the Drug MDMA, S.J. Peroutka, Ed. Kluwer Academic Publishers, Boston, MA, 1990, pp 171-199.
12. S.F. Ali, G.D. Newport, A.C. Scallet, Z. Binienda, S.A. Ferguson, J.R. Bailey, M.G. Paule, and W. Slikker. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective sertonergic depletion in the nonhuman primate. Neurotox. Terat. 15: 91-96 (1993).
13. M.I. Colado and A.R. Green. A study of the mechanism of MDMA ("Ecstasy")-induced neurotoxicity of 5-HT neurons using chlormethiazole, dizocilpine and other protective compounds. Br. J. Pharmacol. 111: 131-136 (1994).
14. M.Y. Yousif, R.L. Fitzgerald, N. Narasimhachari, J.A. Rosecrans, R.V. Blanke, and R.A. Glennon. Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. Drug Alcohol Depend. 26: 127-135 (1990).
15. K.M. Hegadoren, G.B. Baker, and R.T. Coutts. The simultaneous separation and quantitation of the enantiomers of MDMA and MDA using gas chromatography with nitrogen-phosphorus detection. Res. Comm. Subst. Abuse 14: 67-80 (1993).
16. H.K. Lim and R.L. Foltz. In vivo and in vitro metabolism of 3,4-(methylenedioxy) methamphetamine in rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1: 370-378 (1988).
17. H.K. Lim, S. Zeng, D.M. Chei, and R.L. Foltz. Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by capillary gas chromatography-mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionization. J. Pharm. Biomed. Anal. 10: 657-665 (1992).
18. H.K. Lim, Z. Su, and R.L. Foltz. Stereoselective disposition: Enantioselective quantitation of 3,4-(methylenedioxy)methamphetamine and three of its metabolites by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biol. Mass Spectrom. 22: 403-411 (1993).
19. H.J. Helmlin, K. Bracher, D. Bourquin, D. Vonlanthen, and R. Brenneisen. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J. Anal. Toxicol. 20: 432-440 (1996).
20. H.K. Lim and R.L. Foltz. Identification of metabolites of 3,4-(methylenedioxy)-methamphetamine in human urine. Chem. Res. Toxicol. 2: 142-143 (1989).
21. J. Ortuño, N. Pizarro, M. Farré, M. Mas, J. Segura, J. Camí, R. Brenneisen, and R. de la Torre. Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. J. Chromatogr. B 723: 221-232 (1999).
22. H.K. Ensslin, K.-A. Kovar, and H.H. Maurer. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B 683: 189-197 (1996).
23. R.L. Fitzgerald, R.V. Blanke and A. Poklis. Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 2: 241-248 (1990).
24. R.A. Lyon, R.A. Glennon, and M. Titeler. 3,4-methylenedioxymethamphetamine (MDMA): stereoselective interactons at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88: 525-526 (1986).
25. G.M. Marquardt, V. DiStefano, and L.L. Ling. Pharmacological and toxicological effects of beta-3,4-methylenedioxymethamphetamine isomers. Toxicol. Appl. Pharmacol. 45: 675-683 (1978).
26. F. Tagliaro, G. Manetto, S. Bellini, D. Scarcella, F.P. Smith, and M. Marigo. Simultaneous chiral separation of MDA, MDMA, MDEA, ephedrine, amphetamine and methamphetamine by capillary electrophoresis in uncoated and coated capillaries with beta-cyclodextrin as chiral sector: application to urine and hair. Electrophoresis 19: 42-50 (1998).
27. R.L. Fitzgerald, R.V. Blanke, R.A. Glennon, M.Y. Yousif, J.A. Rosecrans, and A. Poklis. Determination of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine enantiomers in whole blood. J. Chromatogr. 490: 59-69 (1989).
28. M. Lanz, R. Brenneisen, and W. Thormann. Enantioselective determination of 3,4-methylenedioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 18: 1035-1043 (1997).
29. K.M. Hegadoren, G.B. Baker, and R.T. Coutts. The simultaneous separation and quantitation of the enantiomers of MDMA and MDA using gas chromatography with nitrogen-phosphorus detection. Res. Commun. Subst. Abuse 14: 67-80 (1993).
30. K.M. Hegadoren, G.B. Baker, and R.T. Coutts. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain. J. Pharmacol. Toxicol. Meth. 34: 117-123 (1995).
31. K.A. Moore, A. Mozayani, M.F. Fierro, and A. Poklis. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci. Int. 83: 111-119 (1996).
32. K. Matsushima, T. Nagai, and S. Kamiyama. Optical isomer analysis of 3,4-methylene-dioxyamphetamine analogues and their stereoselective disposition in rats. J. Anal. Toxicol. 22: 33-39 (1998).
33. D. Hensley and J.T. Cody. Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyamphetamine (MDEA) enantiomers by CC-MS. J. Anal. Toxicol. 23: 518-523 (1999).
34. P. Kintz and N. Samyn. Determination of "ecstasy" components in alternative biological specimens. J. Chromatogr. 733: 137-143 (1999).
35. R.E. Michel, A.B. Rege, and W.J. George. High-pressure liquid chromatography/electrochemical detection method for monitoring MDA and MDMA in whole blood and other biological tissues. J. Neurosci. Meth. 50: 61-66 (1993).
36. E.R. Garrett, K. Seyda, and P. Marroum. High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding. Acta Pharm. Nord. 3: 9-14 (1991).
37. H.J. Helmlin and R. Brenneisen. Determination of psychotropic phenylalkylamines in biological matrices by high performance liquid chromatography with photodiode-array detection. J. Chromatogr. 593: 87-94 (1992).
38. 38. Product Insert, Abuscreen Online 90 ml Kit for Amphetamines (1000 ng/mL CO) 1996, Roche Diagnostic Corp., Indianapolis, IN.
39. Product Insert, Abuscreen Online AMP 500 ng/mL CO 1999, Roche Diagnostic Corp., Indianapolis, IN.
40. Product Insert, COBAS Integra 700 Amphetamines Optional Applications 1998, Roche Diagnostics GmbH, D-68298 Mannheim, Germany.
41. Product Insert, Abuscreen OnLineHS Amp/MDMA 300 ng/mL CO 2000, Roche Diagnostic Corp., Indianapolis, IN.
42. ®II Monoclonal Amphetamine/Methamphetamine Assay 1998 Dade Behring, Cupertino, CA.
43. Product Insert, CEDIA DAU Amphetamines 1997, Microgenics Corp., Pleasanton, CA.
44. Product Insert, TDx Amphetamine/Methamphetamine II 1996, Abbott Laboratories Diagnostic Division, Abbott Park, IL.
45. K.S. Kalasinsky and T. Schaefer. Forensic application of an automated drug profiling system. J. Anal. Toxicol. 19: 412-418 (1995).
46. P. Kintz and C. Giroud. Immunoassay responses of MBDB. J. Anal. Toxicol. 21: 589-590 (1997).
47. G.W. Kunsman, B. Levine, J.J. Kuhlman, R.L. Jones, R.O. Hughes, C.I. Fujiyama, and M.L. Smith. MDA-MDMA concentrations in urine specimens. J. Anal. Toxicol. 20: 517-521 (1996).